Evidence · Randomised trial
The efficiency and safety of low-dose intravenous indomethacin for closure of patent ductus arteriosus in preterm neonate: a randomized controlled trial.
- Acute kidney injury
- Cardiovascular
- Medical
- Metabolic, endocrine and renal
- Patent ductus arteriosus
Summary
This randomised controlled non-inferiority trial from a Thai hospital compared a two-dose low-dose intravenous indomethacin regimen with the conventional three-dose regimen for closure of patent ductus arteriosus in preterm neonates. It assessed both efficacy of ductal closure and safety, particularly renal impairment and gastrointestinal complications. The trial ran from 2021 to 2024 and was retrospectively registered. The abstract provided is truncated, so detailed results and eligibility criteria are not available.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.